MedPage Today on MSN10h
STRIDE: Semaglutide Shows it Has Legs in Peripheral Artery Disease
CHICAGO -- Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building ...
STAT10h
Peter Marks, FDA’s top vaccine regulator, forced out
Top FDA official Peter Marks was forced to resign as the director of the Center for Biologics Evaluation and Research.
BioPharma Dive11h
Peter Marks, FDA’s top vaccine official, resigns
In his resignation letter, Marks cited disagreement with HHS Secretary Robert F. Kennedy Jr., who he said pushed ...
PipelineReview.com20h
Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors
PARIS, France I March 28, 2025 I The US Food and Drug Administration (FDA) has approved Qfitlia (fitusiran), the first antithrombin-lowering (AT) therapy for ...
Sanofi: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors
Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors Qfitlia (fitusiran), the first antithrombin-lowering therapy in hemophilia, offers consistent prot ...